Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

被引：2
|
作者：
Jurczak, Wojciech [1 ]
Zinzani, Pier Luigi [2 ]
Gaidano, Gianluca [3 ]
Goy, Andre [4 ]
Provencio, Mariano [5 ]
Nagy, Zsolt [6 ]
Robak, Tadeusz [7 ]
Maddocks, Kami J. [8 ]
Buske, Christian [9 ]
Ambarkhane, Sumeet [10 ]
Winderlich, Mark [10 ]
Dirnberger-Hertweck, Maren [10 ]
Endell, Jan [10 ]
Blum, Kristie A. [8 ]
机构：
[1] Jagiellonian Univ, Dept Hematol, Krakow, Poland
[2] Univ Bologna, Inst Hematol, Bologna, Italy
[3] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy
[4] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[5] Univ Hosp Puerta Hierro, Dept Med Oncol, Madrid, Spain
[6] Semmelweis Univ, First Dept Internal Med, Budapest, Hungary
[7] Med Univ Lodz, Dept Hematol, Lodz, Poland
[8] Ohio State Univ Comprehens Canc Ctr, Div Hematol, Dept Internal Med, Columbus, OH USA
[9] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, Ulm, Germany
[10] MorphoSys AG, Martinsried, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.623.623
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
623
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Taniwaki, M.
    Ogura, M.
    Matsumoto, Y.
    Uchida, T.
    Ohmachi, K.
    Ando, K.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Lenalidomide response in relapsed/refractory diffuse large B-cell non-Hodgkin's lymphoma
    Lossos, Izidore S.
    Wiernik, Peter H.
    Justice, Glen
    Tuscano, Joseph M.
    Cole, Craig E.
    Vose, Julie M.
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Habermann, Thomas M.
    BLOOD, 2007, 110 (11) : 756A - 756A
  • [43] Incidence of second primary malignancies (SPM) in relapsed/refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) patients in England
    Miret, M.
    Lee, S.
    Vegni, F. E.
    Hindocha, P.
    Cirneanu, L.
    Lymperopoulou, C.
    Markov, E.
    Hitov, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S780 - S781
  • [44] Incidence of second primary malignancies (SPMS) in relapsed/refractory (r/r) b-cell non-hodgkin's lymphoma (NHL) and multiple myeloma (MM) patients in England
    Anderson, Amanda M.
    Miret, Montserrat
    Hindocha, Pooja
    Cirneanu, Lorena
    Lymperopoulou, Christina
    Markov, Emanuil
    Hitov, Svetomir
    Vegni, Ferdinando E.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 512 - 512
  • [45] Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)
    Kang, Hye J.
    Lee, Seung S.
    Kim, Kyeong M.
    Choi, Tae H.
    Cheon, Gi J.
    Kim, Won S.
    Suh, Cheolwon
    Yang, Sung H.
    Lim, Sang M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (02) : 136 - +
  • [46] Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Ohmachi, Ken
    Ando, Kiyoshi
    Ogura, Michinori
    Uchida, Toshiki
    Itoh, Kuniaki
    Kubota, Nobuko
    Ishizawa, Kenichi
    Yamamoto, Joji
    Watanabe, Takashi
    Uike, Naokuni
    Choi, Ilseung
    Terui, Yasuhito
    Usuki, Kensuke
    Nagai, Hirokazu
    Uoshima, Nobuhiko
    Tobinai, Kensei
    CANCER SCIENCE, 2010, 101 (09) : 2059 - 2064
  • [47] Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL)
    Evens, Andrew M.
    Gordon, Leo I.
    Patton, David
    Rosen, Steven T.
    Winter, Jane N.
    Kline, Justin
    Van Besien, Koen
    Smith, Sonali M.
    BLOOD, 2008, 112 (11) : 700 - 700
  • [48] A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin's lymphoma (NHL).
    Williams, M. E.
    Cohen, P.
    Tulpule, A.
    Van der Jagt, R. H.
    Herst, J. A.
    Bessudo, A.
    Lemieux, B.
    Schwartzberg, L. S.
    Oliver, J. W.
    Robinson, K. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 429S - 429S
  • [49] Clofarabine (CLO) Has Single Agent Activity in Relapsed and Refractory Non-Hodgkin Lymphoma (NHL) Including Rituximab (R)-Refractory Patients (pts)
    Nabhan, Chadi
    Bitran, Jacob David
    Fried, Walter
    Galvez, Angel G.
    Magid, Laura
    Tolzien, Kathy
    Dewey, Wendy
    Venugopal, Parameswaran
    BLOOD, 2009, 114 (22) : 380 - 380
  • [50] Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).
    Villasboas, Jose Caetano
    Kline, Justin Paul
    Lazaryan, Aleksandr
    Bartlett, Nancy L.
    Hernandez-Ilizaliturri, Francisco J.
    Awan, Farrukh Tauseef
    Geethakumari, Praveen Ramakrishnan
    Karmali, Reem
    Shune, Leyla
    Lansigan, Frederick
    Reeder, Craig B.
    Diefenbach, Catherine S. Magid
    Sharon, Elad
    Atherton, Pamela J.
    Fiskum, Jack
    Yin, Jun
    Adjei, Alex A.
    Ansell, Stephen M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
12345